The efficacy of sodium channel blockers to prevent phencyclidine-induced cognitive dysfunction in the rat: Potential for novel treatments for schizophrenia

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 1, 2011, Pages 100-113

  Large, Charles H ^a   Bison, Silvia ^a   Sartori, Ilaria ^a   Read, Kevin D ^a,d   Gozzi, Alessandro ^a,e   Quarta, Davide ^a   Antolini, Marinella ^a   Hollands, Emma ^b   Gill, Catherine H ^b   Gunthorpe, Martin J ^b   Idris, Nagi ^c   Neill, Jo C ^c   Alvaro, Giuseppe S ^a  

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e CENTER FOR NANOTECHNOLOGY INNOVATION NEST   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [[(2 FLUOROPHENYL)METHYL]OXY]PHENYL] 7 METHYL 1,7 DIAZASPIRO[4.4]NONAN 6 ONE; 5 [4 [[(2 FLUOROPHENYL)METHYL]OXY]PHENYL]PROLINAMIDE; GSK 2; GSK 3; LAMOTRIGINE; PHENCYCLIDINE; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD VOLUME; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; EMBRYO; FEMALE; FRONTAL CORTEX; LEARNING; MALE; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANIMALS; COGNITION DISORDERS; FEMALE; MALE; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; REVERSAL LEARNING; SCHIZOPHRENIA; SODIUM CHANNEL BLOCKERS; TREATMENT OUTCOME;

EID: 79959511018     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.178475     Document Type: Article

References (44)

1. Adams B and Moghaddam B (1998) Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18:5545-5554. (Pubitemid 28311969)
2. Aldenkamp AP and Baker G (2001) A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav 2:85-91.
3. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, and Krystal JH (2000) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 57:270-276. (Pubitemid 30140436)
4. Boxerman JL, Hamberg LM, Rosen BR, and Weisskoff RM (1995) MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 34:555-566.
5. Brody SA, Geyer MA, and Large CH (2003) Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) 169:240-246. (Pubitemid 37255516)
6. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
7. Cunningham MO and Jones RS (2000) The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 39:2139-2146. (Pubitemid 30645637)
8. Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, and Dursun SM (2008) Glutamate and the neural basis of the subjective effects of ketamine: a pharmacomagnetic resonance imaging study. Arch Gen Psychiatry 65:154-164. (Pubitemid 351214314)
9. Duncan GE, Miyamoto S, Leipzig JN, and Lieberman JA (1999) Comparison of brain metabolic activity patterns induced by ketamine, MK-801, and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res 843:171-183. (Pubitemid 29488707)
10. Dursun SM and Deakin JF (2001) Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol 15:297-301. (Pubitemid 34024249)
11. Dursun SM, McIntosh D, and Milliken H (1999) Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatry 56:950. (Pubitemid 29480132)
12. Friston KJ, Jezzard P, and Turner R (1994) Analysis of functional MRI time-series. Hum Brain Mapp 1:153-171.
13. Goff DC, Keefe R, Citrome L, Davy K, Krystal JH, Large C, Thompson TR, Volavka J, and Webster EL (2007) Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol 27:582-589. (Pubitemid 351339444)
14. Gozzi A, Ceolin L, Schwarz A, Reese T, Bertani S, Crestan V, and Bifone A (2007) A multimodality investigation of cerebral hemodynamics and autoregulation in phMRI. Magnetic Resonance Imaging, 25:826-833. (Pubitemid 47081368)
15. Gozzi A, Large CH, Schwarz A, Bertani S, Crestan V, and Bifone A (2008a) Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology 33:1690-1703. (Pubitemid 351684709)
16. Gozzi A, Schwarz A, Crestan V, and Bifone A (2008b) Drug-anaesthetic interaction in phMRI: the case of the pyschotomimetic agent phencyclidine. Magn Reson Imaging 26:999-1006.
17. Hauser RA (2009) New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy. Parkinsonism Relat Disord 15 (Suppl 3):S17-S21.
18. Helton DR, Tizzano JP, Monn JA, Schoepp DD, and Kallman MJ (1998) Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284:651-660. (Pubitemid 28086655)
19. Hennig J, Nauerth A, and Friedburg H (1986) RARE imaging: a fast imaging method for clinical MR. Magn Reson Med 3:823-833. (Pubitemid 17233280)
20. Hunt MJ, Garcia R, Large CH, and Kasicki S (2008) Modulation of high-frequency oscillations associated with NMDA receptor hypofunction in the rodent nucleus accumbens by lamotrigine. Prog Neuropsychopharmacol Biol Psychiatry 32:1312-1319.
21. Idris NF, Repeto P, Neill JC, and Large CH (2005) Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology (Berl) 179:336-348.
22. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
23. Jackson ME, Homayoun H, and Moghaddam B (2004) NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci 101:8467-8472. (Pubitemid 38736598)
24. Kremer I, Vass A, Gorelik I, Bar G, Blanaru M, Javitt DC, and Heresco-Levy U (2004) Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 56:441-446. (Pubitemid 39195324)
25. Krystal JH, Anand A, and Moghaddam B (2002) Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry 59:663-664. (Pubitemid 34747249)
26. Lamensdorf I, Youdim MB, and Finberg JP (1996) Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 67:1532-1539. (Pubitemid 26314210)
27. Large CH, Webster EL, and Goff DC (2005) The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl) 181:415-436. (Pubitemid 41480891)
28. Large CH (2007) Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol 21:283-301.
29. Large CH, Di Daniel E, Li X, and George MS (2009a) Neural network dysfunction in bipolar depression: clues from the efficacy of lamotrigine. Biochem Soc Trans 37:1080-1084.
30. Large CH, Kalinichev M, Lucas A, Carignani C, Bradford A, Garbati N, Sartori I, Austin NE, Ruffo A, Jones DN, et al. (2009b) The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat. Epilepsy Res 85:96-106.
31. Moghaddam B, Adams B, Verma A, and Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2927. (Pubitemid 27155025)
32. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, and Harte MK (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128:419-432.
33. Paxinos G and Watson C (1998) The Rat Brain in Stereotactic Coordinates. Academic Press, San Diego.
34. Quarta D, Di Francesco C, Melotto S, Mangiarini L, Heidbreder C, and Hedou G (2009) Systemic administration of ghrelin increases extracellular dopamine in the shell but not the core subdivision of the nucleus accumbens. Neurochem Int 54:89-94.
35. Quarta D and Large CH (2010) Effects of lamotrigine on PCP-evoked elevations in monoamine levels in the medial prefrontal cortex of freely moving rats. J Psychopharmacol doi:10.1177/0269881110385598.
36. Schwarz AJ, Danckaert A, Reese T, Gozzi A, Paxinos G, Watson C, Merlo-Pich EV, and Bifone A (2006) A stereotaxic MRI template set for the rat brain with tissue class distribution maps and co-registered anatomical atlas: application to pharmacological MRI. Neuroimage 32:538-550. (Pubitemid 44149167)
37. Schwarz AJ, Whitcher B, Gozzi A, Reese T, and Bifone A (2007) Study-level wavelet cluster analysis and data-driven signal models in pharmacological MRI. J Neurosci Methods 159:346-360. (Pubitemid 44920262)
38. Southam E, Pereira R, Stratton SC, Sargent R, Ford AJ, Butterfield LJ, Wheable JD, Beckett SR, Roe C, Marsden CA, et al. (2005) Effect of lamotrigine on the activities of monoamine oxidases A and B in vitro and on monoamine disposition in vivo. Eur J Pharmacol 519:237-245. (Pubitemid 41278544)
39. Tiihonen J, Hallikainen T, Ryynänen OP, Repo-Tiihonen E, Kotilainen I, Eronen M, Toivonen P, Wahlbeck K, and Putkonen A (2003) Lamotrigine in treatmentresistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 54:1241-1248. (Pubitemid 37464870)
40. Upton N, Blackburn TP, Campbell CA, Cooper D, Evans ML, Herdon HJ, King PD, Ray AM, Stean TO, Chan WN, et al. (1997) Profile of SB-204269, a mechanistically novel anticonvulsant drug, in rat models of focal and generalized epileptic seizures. Br J Pharmacol 121:1679-1686. (Pubitemid 27343396)
41. Weissman AD, Dam M, and London ED (1987) Alterations in local cerebral glucose utilization induced by phencyclidine. Brain Res 435:29-40. (Pubitemid 18009769)
42. Whitcher B, Schwarz AJ, Barjat H, Smart SC, Grundy RI, and James MF (2005) Wavelet-based cluster analysis: data-driven grouping of voxel time courses with application to perfusion-weighted and pharmacological MRI of the rat brain. Neuroimage 24:281-295. (Pubitemid 41359025)
43. Worsley KJ, Evans AC, Marrett S, and Neelin P (1992) A three-dimensional statistical analysis for CBF activation studies in human brain. J Cereb Blood Flow Metab 12:900-918.
44. Xie X and Hagan RM (1998) Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 38:119-130. (Pubitemid 28479447)